Literature DB >> 10554796

Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.

M L Den Boer1, P Kapaun, R Pieters, K M Kazemier, G E Janka-Schaub, A J Veerman.   

Abstract

Contradictory data have been reported about the prognostic value of myeloid antigen co-expression (My+) in childhood acute lymphoblastic leukaemia (ALL). In the present study the methyl thiazol tetrazoliumbromide (MTT) assay was used to compare the in vitro cytotoxicity of 14 drugs between 60 My+ (CD13+ and/or CD33+) and 107 My- ALL children at initial diagnosis. P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), major vault protein/lung resistance protein (LRP) and the intracellular daunorubicin concentration were studied by flow cytometry. My+ ALL samples were significantly more resistant, i.e. between 1.1- and 2.9-fold, to daunorubicin, doxorubicin, idarubicin, mitoxantrone, vincristine, 6-thioguanine, 6-mercaptopurine, teniposide, etoposide and ifosfamide compared with My- ALL samples. My- and My+ ALL did not significantly differ in sensitivity to prednisolone, dexamethasone, L-asparaginase and cytarabine. Comparable results were found when only common and preB ALL cases were analysed. Drug resistance in My+ ALL was not related to increased expression of P-gp, MRP or LRP compared with My- ALL (ratio My+/My-:P-gp 0.8, MRP 1.0, LRP 1.1). Accumulation and retention of daunorubicin did not significantly differ between My- and My+ ALL cells (ratio My+/My-: accumulation 1.2, retention 1.3). Therefore the nature of drug resistance in My+ ALL remains unknown. The lack of prognostic value for My+ in childhood ALL may be explained by the responsiveness of My+ ALL to glucocorticoids, L-asparaginase and cytarabine. In addition, the currently intensive treatment regimens may apply drug doses which are simply high enough to overcome the mild resistance to anthracyclines, mitoxantrone, vincristine, thiopurines, epipodophyllotoxins and ifosfamide in childhood My+ ALL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554796     DOI: 10.1046/j.1365-2141.1999.01440.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.

Authors:  Jan Styczynski; Mariusz Wysocki; Robert Debski; Krzysztof Czyzewski; Beata Kolodziej; Beata Rafinska; Malgorzata Kubicka; Sylwia Koltan; Andrzej Koltan; Monika Pogorzala; Andrzej Kurylak; Dorota Olszewska-Slonina; Walentyna Balwierz; Edyta Juraszewska; Maria Wieczorek; Igor Olejnik; Maryna Krawczuk-Rybak; Marta Kuzmicz; Jerzy Kowalczyk; Jolanta Stefaniak; Wanda Badowska; Danuta Sonta-Jakimczyk; Tomasz Szczepanski; Michal Matysiak; Iwona Malinowska; Elzbieta Stanczak; Jacek Wachowiak; Benigna Konatkowska; Lidia Gil; Anna Balcerska; Lucyna Maciejka-Kapuscinska
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-02       Impact factor: 4.553

2.  ATP Binding Cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia.

Authors:  Stuart S Winter; Jerec Ricci; Li Luo; Debbie M Lovato; Hadya M Khawaja; Tasha Serna-Gallegos; Natalie Debassige; Richard S Larson
Journal:  Health (Irvine Calif)       Date:  2013-05

3.  Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients

Authors:  Dikshat Gopal Gupta; Neelam Varma; Shano Naseem; Man Updesh Singh Sachdeva; Parveen Bose; Jogeshwar Binota; Ashish Kumar; Minakshi Gupta; Palak Rana; Preeti Sonam; Pankaj Malhotra; Amita Trehan; Alka Khadwal; Subhash Varma
Journal:  Turk J Haematol       Date:  2021-10-07       Impact factor: 1.831

4.  Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol.

Authors:  Eddy Supriyadi; Anjo J P Veerman; Ignatius Purwanto; Peter M Vd Ven; Jacqueline Cloos
Journal:  J Oncol       Date:  2012-11-26       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.